---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013663"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:26:47.555793+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma completes NEXICART-2 enrollment; topline results Q3 2026

## Summary
- Enrollment complete for 40-patient BLA-enabling Phase 2 trial NEXICART-2 (NCT06097832) in relapsed/refractory AL Amyloidosis.
- Topline results expected Q3 2026, followed by BLA submission and planned commercial launch for NXC-201.
- Onboarded Chief Medical Officer Richard Graydon, MD, PhD, formerly of Merck and Johnson & Johnson.
- NXC-201 has FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations; market for AL Amyloidosis estimated at $6B in 2025.

## SEC filing metadata
- accession: 0001493152-26-013663
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315226013663/0001493152-26-013663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315226013663/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013663
- JSON: https://secwatch.observer/filing/0001493152-26-013663.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.